Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticlesCitation formats

  • External authors:
  • Neazar E Baghdadi
  • Benjamin P Burke
  • Tahani Alresheedi
  • Shubhanchi Nigam
  • Abdu Saeed
  • Farooq Almutairi
  • Juozas Domarkas
  • Stephen J Archibald

Standard

Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles. / Baghdadi, Neazar E; Burke, Benjamin P; Alresheedi, Tahani; Nigam, Shubhanchi; Saeed, Abdu; Almutairi, Farooq; Domarkas, Juozas; Khan, Abid; Archibald, Stephen J.

In: Dalton Transactions, 27.01.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Baghdadi, NE, Burke, BP, Alresheedi, T, Nigam, S, Saeed, A, Almutairi, F, Domarkas, J, Khan, A & Archibald, SJ 2021, 'Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles', Dalton Transactions. https://doi.org/10.1039/d0dt02626c

APA

Baghdadi, N. E., Burke, B. P., Alresheedi, T., Nigam, S., Saeed, A., Almutairi, F., Domarkas, J., Khan, A., & Archibald, S. J. (2021). Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles. Dalton Transactions. https://doi.org/10.1039/d0dt02626c

Vancouver

Baghdadi NE, Burke BP, Alresheedi T, Nigam S, Saeed A, Almutairi F et al. Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles. Dalton Transactions. 2021 Jan 27. https://doi.org/10.1039/d0dt02626c

Author

Baghdadi, Neazar E ; Burke, Benjamin P ; Alresheedi, Tahani ; Nigam, Shubhanchi ; Saeed, Abdu ; Almutairi, Farooq ; Domarkas, Juozas ; Khan, Abid ; Archibald, Stephen J. / Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles. In: Dalton Transactions. 2021.

Bibtex

@article{972f5a3e60da447b9771c119ce42bcc1,
title = "Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles",
abstract = "The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.",
author = "Baghdadi, {Neazar E} and Burke, {Benjamin P} and Tahani Alresheedi and Shubhanchi Nigam and Abdu Saeed and Farooq Almutairi and Juozas Domarkas and Abid Khan and Archibald, {Stephen J}",
year = "2021",
month = jan,
day = "27",
doi = "10.1039/d0dt02626c",
language = "English",
journal = "Dalton Transactions",
issn = "1477-9226",
publisher = "Royal Society of Chemistry",

}

RIS

TY - JOUR

T1 - Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles

AU - Baghdadi, Neazar E

AU - Burke, Benjamin P

AU - Alresheedi, Tahani

AU - Nigam, Shubhanchi

AU - Saeed, Abdu

AU - Almutairi, Farooq

AU - Domarkas, Juozas

AU - Khan, Abid

AU - Archibald, Stephen J

PY - 2021/1/27

Y1 - 2021/1/27

N2 - The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.

AB - The CXCR4 chemokine receptor is an important biomolecular target in cancer diagnostics and therapeutics. In a new multivalent approach, iron oxide nanoparticles were conjugated with multiple binding units of a low affinity azamacrocylic CXCR4 antagonist. The silica coated nanostructure has good suspension stability, a mode size of 72 nm and high affinity for CXCR4, showing >98% inhibition of anti-CXCR4 mAb binding in a receptor binding competition assay on Jurkat cells.

U2 - 10.1039/d0dt02626c

DO - 10.1039/d0dt02626c

M3 - Article

C2 - 33502425

JO - Dalton Transactions

JF - Dalton Transactions

SN - 1477-9226

ER -